The signing of the National
Cancer Act in 1971 was designed to take laboratory discoveries rapidly from the bench to the bedside. A "war on
cancer" had been declared. Combination cytotoxic
chemotherapy was predicted to cure all
cancers, based on the stunning success in treating childhood
leukemia.
Breast cancer treatments were primitive;
radical mastectomy and radiation were standard of care for disease that had not spread. Ablative endocrine surgery (
oophorectomy,
hypophysectomy, and
adrenalectomy) was a palliative last option for metastatic
breast cancer. However, only 30% responded, surviving for only 1 or 2 years: every patient soon died. The discovery of the
estrogen receptor (ER) and translation to
breast cancer treatment triggered a revolution in women's health. Two important but interconnected events occurred in 1972 at the Worcester Foundation for Experimental Biology (WFEB) that would exploit the
breast tumor ER as the first target to save lives and prevent
breast cancer development. Two new groups of medicines-selective ER modulators (
SERMs) and
aromatase inhibitors (AIs)-would continue the momentum of research at the WFEB to improve women's health. Here, we recount the important progress made in women's health based on knowledge of the endocrinology of
breast cancer. We propose future opportunities in
SERM therapeutics to "refresh" the current standards of care for
breast cancer treatment. The opportunity is based on emerging knowledge about acquired resistance to long-term adjuvant AI
therapy used to treat
breast cancer.